A retrospective study to evaluate Cost and efficacy of low-dose pembrolizumab in the treatment of patients with non small cell lung cancer
Latest Information Update: 21 Sep 2021
At a glance
- Drugs Pembrolizumab (Primary) ; Antineoplastics
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
Most Recent Events
- 21 Sep 2020 Results presented at the 45th European Society for Medical Oncology Congress
- 05 Jun 2020 New trial record
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology